product name MSDC-0160
Description: MSDC-0160 (also called CAY10415), a thiazolidinedione analog, is the prototypical mTOT-modulating insulin sensitizer being investigated to treat diabetes and Alzheimers disease. It is an insulin sensitizer without the peroxisome proliferator–activated receptor-γ (PPAR-γ)-dependent side effects. Co-incubation of islets with MSDC-0160 and IGF-1 reduces the resistance of insulin-signaling pathway and preserves insulin content. MSDC-0160 at 50μM alone also prevents the loss of insulin content significantly. Besides that, treatment of MSDC-0160 increases the phosphorylation of AMPK and reduces mTOR phosphorylation. Moreover, MSDC-0160 is also found to display pro-survival effects in human islets via reducing the level of cleaved caspase-3 and increasing the expression of apoptosis-related genes such as bcl2.
References: PLoS One. 2013 May 1;8(5):e62012; Gene Regul Syst Bio. 2007 Sep 17;1:73-82.
370.42
Formula
C19H18N2O4S
CAS No.
146062-49-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
CAY10415
other peoduct :
| In Vitro |
In vitro activity: MSDC-0160 reduces resistance in the insulin/IGF-1 signaling pathway and restores IGF-1-induced Akt and GSK-3 phosphorylation. MSDC-0160 in combination with IGF-1 and 8 mM glucose increases β-cell specific gene expression of insulin, pdx1, nkx6.1, and nkx2.2, and maintains insulin content without altering glucose-stimulated insulin secretion. Furthermore, MSDC-0160 promotes human β-cell differentiation and reduces the expression of markers of apoptosis. Kinase Assay: MSDC-0160 at 50μM alone also prevents the loss of insulin content significantly. Besides that, treatment of MSDC-0160 increases the phosphorylation of AMPK and reduces mTOR phosphorylation. Moreover, MSDC-0160 is also found to display pro-survival effects in human islets via reducing the level of cleaved caspase-3 and increasing the expression of apoptosis-related genes such as bcl2. Cell Assay: MSDC-0160 exerts prevention of nuclear translocation with β-catenin localized on the cell membrane or cytoplasm in human β-cells |
|---|---|
| In Vivo | MSDC-0160 (100 mg/kg p.o.) improves insulin sensitivity by resulting in the large decrease in the product of circulating insulin and glucose in diabetic KKAy mice. |
| Animal model | Diabetic KKAy mice |
| Formulation & Dosage | Suspended in 1% sodium methyl carboxycellulose/0.01% Tween 20; 100 mg/kg; p.o. |
| References | PLoS One. 2013 May 1;8(5):e62012; Gene Regul Syst Bio. 2007 Sep 17;1:73-82. |
